METHODS OF TREATING PATHOLOGICAL CONDITIONS WITH ANTIBODIES WHICH BIND TO THE COLONY-STIMULATING FACTOR 1 RECEPTOR (CSF1R) Russian patent published in 2020 - IPC A61K39/395 A61P19/02 

FIELD: medicine; immunology.

SUBSTANCE: group of inventions can be used to reduce the level of cytokines in an individual with neoplasia. To reduce the level of cytokines selected from IL-6, IL-1β, IL-8, CCL2, CXCL10, TNF-α, CCL7, CXCL5, CXCL9, CXCL6, MMP-7, MMP-2 and MMP-9, in an individual with neoplasia, administering an effective amount of an antibody which binds to human colony-stimulating factor 1 (CSF1R) receptor, wherein the antibody blocks binding human colony-stimulating factor 1 (CSF1) with human CSF1R and blocks binding of human IL-34 with human CSF1R. Antibody is selected from: a) an antibody comprising a heavy chain comprising the sequence SEQ ID No. 39, and a light chain comprising the sequence SEQ ID No. 46; and b) an antibody comprising a heavy chain comprising the sequence SEQ ID No. 53, and a light chain comprising the sequence SEQ ID No. 60. Group of inventions also relates to a method of treating neoplasia in a subject with an elevated level of said cytokines.

EFFECT: use of this group of inventions enables to reduce the increased level IL-6, IL-1β, IL-8, CCL2, CXCL10, TNF-α, CCL7, CXCL5, CXCL9, CXCL6, MMP-7, MMP-2 and MMP-9 in an individual with neoplasia, reducing the number of monocytic cells.

28 cl, 9 tbl, 7 dwg